Roche, ChanTest Ink Deal to Evaluate Safety of Compounds | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roched has entered into an agreement with ChanTest to evaluate the safety of potential drug compounds.

Under the terms of the deal announced today, ChanTest, an ion channel screening provider, will use Roche's xCelligence System RTCA Cardio Instrument and Cellular Dynamics International's iCell Cardiomyocytes to evaluate pharmacological responses to a number of compounds that have been selected based on their known effects on ion channels.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.